Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B

Journal of Clinical Investigation

Volumn 101, Issue 5, 1998, Pages 1163-1174

  Wahl, Christian ^a   Liptay, Susanne ^a   Adler, Guido ^a   Schmid, Roland M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

AP1; Inflammatory bowel disease; NF B; SW620; Therapy

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESALAZINE; PHORBOL ESTER; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENTERITIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; TRANSCRIPTION REGULATION;

EID: 0032032469     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI992     Document Type: Article

References (46)

1. Svartz, N., 1941. Ett nytt sulfonamidpreparat. Forelopande meddelande. Nord. Mcd. 9:544.
2. Riis, P., P. Anthonsien, H.R. Wulf,. O. Folkenborg, O. Bonnevie, and V. Binder. 1973. The prophylactic effect of salazosulphapyridine in uicerative colitis during long-term treatment: a double-blind trial on patients asymptomatic for one year. Scand. J. Gasirornierol. 8:71-74.
3. Hoult, J.R.S. 1986. Pharmacological and biochemical actions of sulphasalazine. Drugs. 32 (Suppl. 1 ):18-26.
4. Azad Khan, A.K., J. Piris, and S.C. Truelove. 1977. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 2:892-895.
5. Klotz, U., K. Maier, C. Fischer, and K. Heinkel. 198O. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N. Engl. J. Med. 303:1499-1502.
6. Sutherland, L.R., G.R. May, and E.A Shaffer. 1993. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann. Int. Med. 118:540-549.
7. Taggart, A.J., V.C. Neumann, J. Hill, C. Astbury, P. Le Gallez, and J.S. Dixon. 1986. 5-aminosalicylic acid or sulphapyridinc. which is the active moiety of sulphasalazine in rheumatoid arthritis? Drugs. 32 (Suppl. 1):27-34.
8. Bird, H.A. 1995. Sulphasalazine. sulphapyridine or 5-aminosalicylic acid - which is the active moiety in rheumatoid arthritis? Br. J. Rheumatal. 34 (Suppl. 2): 6-19.
9. Carlin, G., R. Djursater, and G. Smedegard. 1989. Inhibitory effects of sulfasalazine and related compounds on Superoxide production by human polymorphonuclear leukocytes. Pharmacol. Toxicol. 65:121-127.
10. Rhodes, J.M., T.C. Bartholomew, and O.P. Jewell. 1981. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut. 22:642-647.
11. Rubinstein, A., K.M. Das, J. Melamed, and R.A. Murphy. 1978. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effect of sulfasalazine in vivo and in vitro. Clin. Exp. Immunol. 33:217-224.
12. Sheldon, PJ., C. Webb, and K.A. Grindulis. 1988. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes -clues to its clinical action? Br. J. Rheumatol. 27:344-349.
13. Fujiwara, M., K. Mitsui, and I. Yamamoto. 1990. Inhibition of proliferative responses and interleukin 2 production by salazosulfapyridine and its metabolites. Jpn. J. Pharmacol. 54:121-132.
14. Gaginella, T.S., and R.E. Walsh. 1992. Sulfasalazine: multiplicity of action. Dig. Dis. Sci. 37:801-812.
15. Grisham, M.B. 1993. Role of reactive oxygen metabolites in inflammatory bowel disease. Curr. Opin. Gastroenterol. 9:971-980.
16. Aruom, O.I., M. Wasil, B. Halliwell, B.M. Hoey, and J. Butler. 1987. The scavenging of oxidants by sulphasalazinc and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem. Pharmacol. 36:3739-3742.
17. Gionchetti, P., C. Guarnieri, M. Campieri, A. Bellusgi, C. Brignola, P. Tannone, M. Miglioli, and C. Barbara. 1991. Scavenger effect of sulfasalazine, 5-Aminosalicylic acid, and osalazine on Superoxide radical generation. Dig. Dis. Sci. 36:174-178.
18. Siebenlist, U., G. Franzoso, and K. Brown. 1994. Structure, regulation and function of NF-κB. Ann. Rev. Cell Biol. 10:405-455.
19. Bacuerle, P.A., and D. Baltimore. 1996. NF-κB: ten years after. Cell. 87: 13-20.
20. Beg, A.A., T.S. Finco, P.V. Nantermet, and A.S. Baldwin Jr. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Mol. Cell. Biol. 13:3301-3310.
21. Palombella, V., O. Rando, A. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. 78:773-785.
22. Brown, K., S. Gerstberger, L. Carlson, G. Franzoso, and U. Siebenlist. 1995. Control of lκB-α proteolysis by site-specific, signal-induced phosphorylation. Science. 267:1485-1488.
23. Thompson, J.E., R.J. Phillips, H. Erdjumant-Bromage, P. Tempst, and S. Ghosh. 1995. IkB-β regulated the persistent response in a biphasic activation of NF-κB. Cell. 80:573-582.
24. Schmid, R.M., N.D. Perkins, C.S. Duckett, P.C. Andrews, and GJ. Nabel. 1991. Cloning of an NF-κB subunit which stimulates HIV transcription in synergy with p65. Nature. 352:733-736.
25. Duckett, C.S., N.D. Perkins, T.F. Kowalik, R.M. Schmid, E.-S. Hunag, A.S. Baldwin, Jr., and GJ. Nabel. 1993. Dimerization of NF-κB2 with RelA (p65) regulates DNA binding, transcriptional activation, and inhibition by an IκB-α (MAD-3). Mol Celt. Biol. 13:1315-1322.
26. Schmid, R.M., S. Liptay, J.C. Belts, and G.J. Nabel. 1994. Structural and functional analysis of NF-κB. J. Biol. Chem. 51:32162-32167.
27. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlciroform extraction. Anal. Biochem. 162:156-159.
28. Omary, M.B., L. deGrandpre, M. McCaffrey. and M.F, Kagnoff. 1992. Biochemical and morphological differentiation of the human colonie epithelial cell line SW620 in the presence of dimethylsulfoxide. J. Cell. Biochem. 48:316-323.
29. Schuerer-Maly, C.-C., L. Eckmann, M.F. Kagnoff, M.T. Falco, and F.E. Maly. 1994. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 81: 85-91.
30. Schreck, R., P. Rieber, and P.A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:2247-2258.
31. Schreck, R., B. Meier, D. Männel, W. Grüge, and P.A. Baeuerle. 1992. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J. Exp. Med. 175:1181-1194.
32. Kopp, E., and S. Ghosh. 1994. inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:956-959.
33. Pierc, J. W., M.A. Read, H. Ding, F. W. Luscinskas, and T. Collins. 1996. Salicylates inhibit IkB-α phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 156:3961-3969.
34. Chiao, P.J., M. Shigeki, and I.M. Verma. 1994. Autoregulation of lκBα activity. Proc. Natl. Acad. Sci. USA. 91:28-32.
35. Ito, C.Y., A.C. Kazantsev, and A.S. Baldwin, Jr. 1994. Three NF-κB sites in the IκB-α promoter are required for induction of gene expression by TNFα. Nucl. Acids. Res. 22:3787-3792.
36. Schenk, H., M. Klein, W. Erdbrügger, and W. Dröge. 1994. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc. Natl. Acad. Sci. USA. 91:1672-1676.
37. Schmidt, K.N., P. Amstad, P. Cerutti, and P.A. Baeuerle. 1995. The roles of hydrogen peroxide and Superoxide as messengers in the activation of transcription factor NF-κB. Chem. Biol. 2:13-22.
38. Frantz, B., and E.A. O'Neill. 1995. The effect of sodium salicylate and aspirin on NF-κB. Science. 270:2017-2019.
39. Das, K.M., M.A. Eastwood, J.P.A. McManus, and W. Sircus. 1973. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 14:631-641.
40. Peppercorn, M.A., and P. Goldman. 1973. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 64:240-245.
41. Neurath, M.F., S. Pettersson, K.-H.M. Meyer zum Büschenfeldc, and W. Strober. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. 2:998-1004.
42. Romano, M.F., A. Lamberti, A. Petrella, R. Bisogni, P. Tassone, S. Formisano, S. Ventuta, and M.C. Turco. 1996. IL-10 inhibits nuclear factor-κB/ Rel nuclear activity on CD3-stimulated human peripheral T lymphocytes. J. Immunol. 156:2119-2123.
43. Takeshita, S., J.R. Gage, T. Kishimoto, D.L. Vredevoe, and O. Martinez-Maza. 1996. Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines.J. Immunol. 156:2591-2598.
44. Auphan, N., J.A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 270:286-290.
45. Scheinman, R.I., P.C. Cogswell, A.K. Lofquist, and A.S. Baldwin Jr. 1995. Role of transcriptional activation of IxBa in mediation of immunosuppression by glucocorticoids. Science. 270:283-286.
46. MacDermott, R.P., S.R. Schloemann, M.J. Berotvich, O.S. Nash, M. Peters, and W.F. Stenson. 1989. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 96:442-448.